Objective: The aim of the present study was to compare the effects of iopanoic acid (IOP) or a saturated solution of potassium iodide (SSKI) administration to patients with toxic diffuse goiters (TDG). Design: Patients with TDG are treated with thionamides and high doses of iodine preoperatively. In this study, two types of preoperative drug regimens were used: propylthiouracil or methimazole plus SSKI for 10 -15 days ðn ¼ 8Þ or IOP for 7 days ðn ¼ 6Þ: Methods: Serum thyroid hormones (total and free thyroxine (T 4 ), total tri-iodothyronine (T 3 ) and reverse T 3 (rT 3 ), were evaluated after 7 days of either SSKI or IOP treatment, and after 10 -15 days of SSKI administration. During thyroidectomy, samples of thyroid gland were obtained to evaluate thyroperoxidase and thyroid H 2 O 2 -generating activities. Results: Serum total T 3 was significantly decreased after 7 days of either treatment, and serum rT 3 was significantly increased in IOP-treated patients. Serum total and free T 4 were unaffected by 7 days of IOP treatment, but decreased after 7 days of SSKI treatment, although significantly diminished levels were only reached after a further 3-8 days of SSKI administration. During both drug regimens, serum TSH remained low (SSKI: 0:159^0:122; IOP: 0:400^0:109 mU=ml). Thyroperoxidase activity was significantly lower in thyroid samples from patients treated with SSKI for 10-15 days than in the thyroid glands from IOP-treated patients. However, thyroid H 2 O 2 generation was inhibited in samples from patients treated with either IOP or SSKI. Conclusions: We show herein that IOP treatment can be effective in the management of hyperthyroidism and that this drug inhibits thyroid NADPH oxidase activity, just as previously described for SSKI, probably due to its iodine content.
Introduction
Toxic diffuse goiter (TDG) is characterized by hypertrophy and hyperplasia of the thyroid gland and hyperthyroidism. In TDG patients, the management of hyperthyroidism can be achieved by treatment with thionamides and iodine preoperatively (1).
Acute iodine administration causes inhibition of thyroid hormone release and reduces thyroid gland vascularity (2, 3). Thus, patients with TDG are usually treated for 10 -15 days with iodine preoperatively, in order to improve the control of thyrotoxicosis and decrease bleeding during surgery.
Apart from the inhibition of thyroid hormone release, thyroid auto-regulation by iodine involves the inhibition of adenylate cyclase activity, iodide transport into thyrocytes, and iodine organification (3 -7). Thyroid iodine organification depends on thyroperoxidase (TPO) activity and thyroid H 2 O 2 generation, a limiting step in thyroid hormone biosynthesis (8). Previous studies have shown that high iodide concentrations inhibit TPO activity in vitro (9). Furthermore, it has recently been demonstrated that the thyroid H 2 O 2 -generating system -NADPH oxidase -is inhibited in TDG patients who receive high doses of iodine preoperatively (10). In fact, Ohayon et al. (11) demonstrated that NADPH oxidase activity is inhibited by iodide in vitro.
Some iodinated radiographic contrast agents, like iopanoic acid (IOP) and sodium ipodate, when used for short periods, have been successful in the treatment of thyrotoxicosis (12) (13) (14) (15) (16) (17) . They seem to be safe, rapid and efficacious drugs to use in hyperthyroid patients before surgery. IOP might release iodine (1 g IOP contains 650 mg iodine) and thus decrease thyroid hormone production and secretion (18 -20) . Nevertheless, this drug is also a potent inhibitor of thyroxine (T 4 ) 5 0 -monodeiodination, blocking the conversion of T 4 to tri-iodothyronine (T 3 ) (19, 21) .
The aim of the present study was to compare the effects of either IOP or iodine administration on thyroid function in TDG patients programmed for thyroidectomy. The study was performed with two types of regimens: one conventional, propylthiouracil (PTU) or methimazole (MMI) plus a saturated solution of potassium iodide (SSKI) for 10 -15 days, and another with PTU or MMI plus IOP for 7 days. We evaluated serum thyroid hormone (total and free T 4 , total T 3 and reverse T 3 (rT 3 )) levels after 7 days of either SSKI or IOP treatment, as well as 10 -15 days after SSKI treatment. TPO iodide oxidation activity and thyroid H 2 O 2 -generating activity (NADPH oxidase) were evaluated in the thyroid samples obtained from these patients during thyroidectomy.
Materials and methods

Materials
NADPH, lyophilized horseradish peroxidase (HRP, grade 1) and glucose oxidase (25 000 U) were purchased from Boehringer (Mannheim, Germany); scopoletin, digitonin and FAD were obtained from Sigma Chemical Co. (St Louis, MO, USA).
Patients
Fourteen patients with TDG were randomly selected to receive either SSKI or IOP prior to surgery (12 females and 2 males). Eight patients (one male, age median: 32.5 years, range: 16 -43 years) received SSKI (5 drops three times per day) for 10 -15 days before thyroidectomy. Six patients (one male, age median: 30.5 years, range: 21 -41 years) received 1 g IOP (Telepaque, Merck do Brasil) daily for 6 days plus 3 g at 12 h before surgery, which took place on the 7th day of treatment. All TDG patients received either PTU (500 -900 mg/day) or MMI (25 -50 mg/day) until the day before surgery. Paranodular thyroid tissue samples were obtained from 13 female patients with cold nodules and normal serum T 4 , T 3 and thyrotropin (TSH) levels who did not receive any treatment before surgery. All patients gave their informed consent. The study was approved by the Institutional Human Research Committee.
Thyroid tissue samples were obtained at thyroidectomy and either freshly processed for NADPH oxidase measurements or stored at 2 20 8C for TPO extraction and activity determination.
Serum hormone levels
Blood samples were collected just before the start of treatment (basal), 7 days afterwards and on the day of surgery (day 7 for IOP-treated patients and day 10 -15 for SSKI-treated patients). Total T 4 , total T 3 and TSH (third generation) were measured using a solid-phase, chemiluminescent enzyme immunoassay (Immulite); free T 4 and rT 3 were measured by RIA and all kits were purchased from Diagnostic Products Corporation, Los Angeles, CA, USA.
Thyroid samples processing
For NADPH oxidase preparations, fresh human thyroid tissue samples (1 g) were cleaned from fibrous tissue or hemorrhagic areas, minced and homogenized in sodium phosphate buffer, pH 7.2, containing 0.25 mol/l sucrose, 0.5 mmol/l dithiothreitol and 1 mmol/l EGTA, using an Ultra-Turrax (IKA, Staufen, Germany). The homogenate was filtered through cheesecloth. The particulate fraction was collected by centrifugation at 3000 g for 15 min at 4 8C and resuspended in 3 ml 50 mmol/l sodium phosphate buffer, pH 7.2, containing 0.25 mol/l sucrose and 2 mmol/l MgCl 2 (buffer A). The pellet was washed twice with 3 ml buffer A and centrifuged at 3000 g for 15 min at 4 8C. The last pellet (P 3000 g ) was gently resuspended in 1 ml buffer A. The supernatant of the first centrifugation was centrifuged at 100 000 g for 1 h at 4 8C. The pellet (microsomal fraction, P 100 000 g ) was washed twice in 2 ml buffer A, and gently resuspended in 0.5 ml buffer A. Protein concentrations were measured by the method of Bradford (22) , using BSA as standard. The particulate fractions (P 3000 g and P 100 000 g ) were incubated with 2.5 mol/l NaOH (30 min, 20 8C) to dissolve particulates before protein determination.
For TPO preparation, thyroid tissue samples (1 g) were cleaned from fibrous tissue or hemorrhagic areas, minced and homogenized in 50 mmol/l TrisHCl buffer pH 7.2, containing 1 mmol/l KI, using an Ultra-Turrax. The homogenate was centrifuged at 100 000 g for 1 h at 4 8C and the pellet was resuspended in 2 ml digitonin (1%, w/v). The mixture was incubated at 4 8C for 24 h and then centrifuged at 100 000 g for 1 h at 4 8C. The supernatant containing solubilized TPO was used for the iodide oxidation assays, as previously described (23, 24) .
Ca
2+ -and NADPH-dependent H 2 O 2 -generating system: NADPH oxidase activity H 2 O 2 formation was measured by incubating samples of thyroid particulate fractions (P 3000 g and P 100 000 g ), at 30 8C, in 1 ml 170 mmol/l sodium phosphate buffer, pH 7.4, containing 1 mmol/l sodium azide, 1 mM EGTA, 1 mmol/l FAD, 1.5 mmol/l CaCl 2 , as previously described (10, 25). The reaction was started by adding 0.2 mmol/l NADPH; aliquots of 100 ml were collected at intervals up to 20 min, and mixed with 10 ml 3 mol/l HCl to stop the reaction and destroy the remaining NADPH. Initial rates of H 2 O 2 formation were determined from eight aliquots of each assay by following the decrease in 0.4 mmol/l scopoletin fluorescence in the presence of HRP (0.5 mg/ml) in 200 mmol/l phosphate buffer, pH 7.8, in a spectrofluorimeter (Hitachi F 4000; Hitachi, Tokyo, Japan), as previously described (10, 25, 26) . The excitation and emission wavelengths were 360 and 460 nm respectively. All measurements were performed at least in triplicate for each particulate preparation and expressed as nmol H 2 O 2 /h. Specific activities were expressed per mg protein (nmol H 2 O 2 /h per mg protein) in the thyroid P 3000 g and P 100 000 g fractions.
TPO iodide oxidation activity
Thyroid peroxidase iodide oxidation assays were performed using 12 mmol/l KI in 50 mmol/l phosphate buffer (pH 7.4), and glucose -glucose oxidase as the H 2 O 2 -generating system, as previously described (23, 24) . The increase in absorbancy at 353 nm (Dabs 353nm ) was followed for 4 min on a U-3300 double-beam spectrophotometer (Hitachi). TPO activity was estimated from the Dabs 353nm /min determined from the linear portion of the reaction curve. One unit of iodide oxidation activity is defined as Dabs 353nm /min ðUÞ ¼ 1:0; and activity was related to the protein concentration in the enzyme preparation (U/g protein).
Analysis of TPO levels by gel electrophoresis and immunoblot TPO preparations (50 mg protein) from one SSKItreated and one IOP-treated patient were submitted to SDS-PAGE using a 6.5% bis-acrylamide gel,
Statistical analysis
Statistical analysis of serum hormone levels at different periods of iodine or IOP treatment was done using the two-way ANOVA (Super ANOVA; Abacus, Berkeley, CA, USA). Serum free T 4 levels in SSKI-treated patients were also analyzed by one-way ANOVA for repeated measures followed by Bonferroni multiple comparison tests. TPO and NADPH oxidase activities were analyzed by ANOVA followed by a Newman -Keuls multiple comparison test. Results are expressed as means^S.E.M.
Results
Basal serum thyroid hormone levels did not differ significantly between the groups of patients studied (IOP or SSKI). Total and free T 4 did not decrease after 7 days of IOP treatment (total T 4 basal: 14:61^1:51; total T 4 7 day: 13:90^1:43 mg=dl; free T 4 basal: 3:190 :45; free T 4 7 day: 3:05^0:36 ng=dl) but were diminished, although not significantly, after 7 days of SSKI treatment (total T 4 basal: 14:47^1:67; total T 4 7 day: 10:56^1:63 mg=dl; free T 4 basal: 2:66^0:46; free T 4 7 day: 2:02^0:37 ng=dl) and reached significantly lower levels after 10 -15 days of SSKI administration (total T 4 : 10:05^1:56 mg=dl; free T 4 : 1:73^0:32 ng=dl), when compared with basal levels (Fig. 1) .
T 3 decreased significantly after 7 days of IOP (basal: 252:40^19:06; 7 day: 162:10^10:21 ng=dl) or SSKI (basal: 226:10^25:57; 7 day: 164:20^19:77 ng=dl) treatment, and rT 3 significantly increased in IOP-treated patients (basal: 0:71^0:12; 7 day: 1:33^0:23 ng=dl) (Fig. 1) . Serum TSH levels remained low in both groups studied (SSKI: 0:159^0:122; IOP: 0:400^0:109 mU=ml; normal range: 0:30 -5:0 mU=ml).
TPO activity is increased in non-treated TDG patients, but in this study TPO activity in the thyroid of SSKI-treated patients did not differ significantly from the activity found in paranodular tissues, while TPO activity was higher in IOP-treated patients, indicating that SSKI administration for 10 -15 days reduces TPO activity more efficiently (Fig. 2) . A TPO immunoblotting also suggested a greater amount of TPO in the thyroid samples from IOP-treated patients than in those from SSKI-treated patients (Fig. 3) .
Thyroid NADPH oxidase activity was not detected in the P 3000 g fraction from tissues of either SSKI-or IOP-treated patients; however, in the P 100 000 g fraction the enzymatic activity was within the normal range in both groups of patients (Fig. 4) .
Discussion
The use of oral radiographic contrast agents like IOP may be useful in the treatment of thyrotoxicosis before surgery, in neonatal hyperthyroidism and in massive L-T 4 ingestion, or when other antithyroid drugs are contraindicated (20) . In the present study, the period of treatment with IOP or SSKI in association with anti-thyroid drugs was sufficient for all to achieve clinical euthyroidism before surgery.
Some authors reported that the use of these agents could induce a rapid decrease in serum T 3 levels, which reached normal levels after 2 -5 days of treatment (13, 27). In the present study, both SSKI and IOP treatment significantly decreased serum T 3 levels to values within the normal range after 7 days of treatment. The finding that rT 3 was significantly increased by IOP treatment is in accord with the previously described action of this drug as a potent T 4 5 0 -deiodinase inhibitor. Thus, IOP might induce serum T 3 decrease due to T 4 deiodinase inhibition; however, SSKI treatment could lead to a direct inhibition of T 3 secretion by the thyroid gland. This hypothesis is in agreement with the fact that SSKI treatment was able to alter serum total and free T 4 levels, which were already decreased, although not significantly, after 7 days, and decreased further 10 -15 days after the beginning of iodine administration.
The effect of excess iodide, accumulated in a short period of time, in the thyroid gland, is known to were submitted to SDS-PAGE using a 6.5% bis-acrylamide gel, for 4 h at 120 V. Electro-transfer of proteins from gel to nitrocellulose was performed for 2 h at 250 mA. The immunoblotting revealed a reasonable signal in a TPO sample from a patient treated with SSKI when compared with an IOP-treated patient.
promote an acute inhibition of the synthesis of iodotyrosines and iodothyronines (4). Increased amounts of iodide transported into the thyrocyte induce the formation of an iodinated compound (3), which could be the mediator for some effects of excess iodine. A decrease in the sodium/iodide symporter 24 h after excess iodide has also been demonstrated in rats, and could explain the escape from iodine administration (28) .
We recently reported (10) that SSKI administration to TDG patients irreversibly inhibited thyroid NADPH oxidase activity in the P 3000 g fraction, even in one patient who received only iodine and propranolol prior to surgery. NADPH oxidase inhibition occurred in the present study in both SSKI-and IOP-treated patients. These findings suggest that IOP releases iodide in vivo, since iodide appears to be a potent inhibitor of this enzymatic system both in vitro (11, 29) and in vivo (10). NADPH oxidase synthesis is dependent on the cAMP cascade stimulated by TSH in thyrocytes (30, 31) . Excess of iodide decreases cAMP in thyroid cells in response to TSH, but the strong inhibitory effect of iodide on thyroid NADPH oxidase, which was only found in the P 3000 g fraction of TDG, is probably not only due to decreased enzyme synthesis, as enzyme activity was within the normal range in the P 100 000 g from the same samples. Besides, TPO synthesis is also stimulated by cAMP, and this enzyme activity was not decreased after 7 days of IOP administration when NADPH oxidase has already been inhibited in the P 3000 g.
Our present findings showing that SSKI administration, but not IOP, is able to significantly decrease TPO activity, maybe due to the longer period of treatment with SSKI than with IOP. These results indicate that iodine might inhibit TPO synthesis, probably due to decreased thyroid response to TSH. Nevertheless, we demonstrate that TPO seems not to be directly inhibited by iodide, at least irreversibly, as has previously been suggested (9). Furthermore, high doses of in vivo PTU or MMI administration did not irreversibly inhibit TPO, as both SSKI-and IOP-treated patients received these drugs during the study.
We conclude that SSKI (10 -15 days) and IOP (7 days) have similar effects on thyroid function and that both are effective in the management of hyperthyroidism prior to surgery. -and NADPH-dependent H 2 O 2 -generating activity were measured in 13 paranodular to cold nodule tissue samples (PN), from eight SSKI-treated and six IOP-treated patients with TDG. Particulate P 3000 g fraction or microsomal P 100 000 g fraction was evaluated.
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